Glycotope GmbH
🇩🇪Germany
Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Solid Tumor, Adult
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Glycotope GmbH
- Target Recruit Count
- 50
- Registration Number
- NCT03360734
- Locations
- 🇪🇸
Glycotope-contracted research facility, Barcelona, Spain
CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Squamous Cell of Head and Neck
- Interventions
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Glycotope GmbH
- Target Recruit Count
- 240
- Registration Number
- NCT02052960
- Locations
- 🇪🇸
Glycotope-contracted Research Facility, Valencia, Spain
🇩🇪Glycotope-contracted Research Facillity, Hannover, Germany
🇮🇹Gycotope-contracted Research Facility, Milan, Italy
PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer
Phase 2
Completed
- Conditions
- Primary Peritoneal CancerFallopian Tube CancerOvarian Epithelial Cancer Recurrent
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-07-15
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Glycotope GmbH
- Target Recruit Count
- 216
- Registration Number
- NCT01899599
- Locations
- 🇬🇧
Investigator, Sutton, United Kingdom
Efficacy and Safety of FSH-GEX™ in Comparison With 150 IU Gonal-f®
- First Posted Date
- 2013-02-18
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Glycotope GmbH
- Target Recruit Count
- 267
- Registration Number
- NCT01794208
- Locations
- 🇭🇺
Glycotope Investigational Site, Tapolca, Hungary
🇩🇪Glycotope Investigational Medical Director, Bielefeld, Germany
Multiple Dose FSH-GEX(TM) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Female Infertility
- Interventions
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Glycotope GmbH
- Target Recruit Count
- 57
- Registration Number
- NCT01477073
- Locations
- 🇳🇱
Glycotope Investigational Site, Groningen, Netherlands
TrasGEX™: Phase 1 Study in Cancer Patients
Phase 1
Completed
- Conditions
- Solid Tumors
- Interventions
- Drug: TrasGEX™
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Glycotope GmbH
- Target Recruit Count
- 37
- Registration Number
- NCT01409343
- Locations
- 🇨🇭
Glycotope Investigational Site, Bellinzona, Switzerland
Single Dose FSH-GEX™ in Healthy Volunteers
Phase 1
Completed
- Conditions
- Female Infertility
- Interventions
- First Posted Date
- 2011-05-17
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Glycotope GmbH
- Target Recruit Count
- 19
- Registration Number
- NCT01354886
- Locations
- 🇳🇱
Glycotope Investigational Site, Groningen, Netherlands
CetuGEX™: Phase 1 Study in Cancer Patients
Phase 1
Completed
- Conditions
- Solid Tumors
- Interventions
- Drug: CetuGEX™
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Glycotope GmbH
- Target Recruit Count
- 41
- Registration Number
- NCT01222637
- Locations
- 🇨🇭
Glycotope Investigational Site, Bellinzona, Switzerland
PankoMab-GEX™: Phase 1 Dose Escalation Study
Phase 1
Completed
- Conditions
- Solid Tumors
- Interventions
- Drug: PankoMab-GEX™
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- Glycotope GmbH
- Target Recruit Count
- 74
- Registration Number
- NCT01222624
- Locations
- 🇨🇭
Glycotope Investigational Site, Bellinzona, Switzerland